Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments

February 28, 2024

https://www.globenewswire.com/news-release/2024/02/28/2836750/0/en/Oculis-Provides-Updates-at-R-D-Day-on-Late-Stage-Clinical-Trials-and-Announces-Key-Leadership-Appointments.html

ZUG, Switzerland, and BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq:OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today provides updates at its in-person and virtual R&D Day on continued progress in advancing its late-stage clinical trials and strengthening the organization with additional senior appointments to its management and advisory teams.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.